Under the Paperwork Reduction Act of 1995, no pens to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10816574		
Filing Date		2004-04-01		
First Named Inventor	Shao	Xiang Lu		
Art Unit		1616		
Examiner Name	A. Soroush			
Attorney Docket Number		LOREAL 3.0-038		

			Remove			
Examiner Cite Par		Patent Number Kind Code		Issue Date Name of Patentee of Applicant		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear
	1	3827999		1974-08-06	Crossland	
	2	4369284		1983-01-18	Chen	
	3	4798853		1989-01-17	Handlin, Jr.	
	4	4976961		1990-12-11	Norbury et al.	
	5	4976963		1990-12-11	Schricker et al.	
	6	5496544		1996-03-05	Mellul et al.	
	7	5510072		1996-04-23	Rosenqvist et al.	
	8	6060072		2000-05-09	Konik et al.	

			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	name of Patentee of Applicant		Relev	s,Columns,Lines wher vant Passages or Rele es Appear	
	1	20020110573	A1	2002-08	l-15	Caes et al.				
	2	20030068344	A1	2003-04	i- 1 0	Ferrari et al.				
If you wis	h to a	dd additional U.S. Publi						d butto		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	T4
1	1	0 299 718	EP			1989-01-18	Raychem Corp			
2	2	0 461 497	EP			1991-12-18	Basf Ag			×
3	3	0 749 746	EP			1996-12-27	Oreal			×
4	4	1 044 673	ΕP			2000-10-18	Oreal			×
5	5	1 103 249	EΡ			2001-05-30	Oreal			×
6	6	1 249 223	EP			2002-10-16	Oreal			

7	7	1 249 226	E₽		2002-10-16	Oreal		×
8	8	2357244	FR		1978-02-03	Minnesota Mining & Mfg		
9	9	2710646	FR		1995-04-07	Lvmh Rech		×
10	10	40-05234	JP		1992-01-09	Taisho Pharma Co Ltd		×
11	11	62-249653	JP		1987-10-30	Kao Corp		
12	12	00/49997	wo		2000-08-31	Oreal et al.		
13	13	02/58643	wo		2002-08-01	Oreal et al.		
14	14	97/17058	wo		1997-05-15	Procter & Gamble		
15	15	97/17059	wo		1997-05-15	Procter & Gamble		
16	16	97/49352	wo		1997-12-31	Gillette Canada et al.		
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add							
	NON-PATENT LITERATURE DOCUMENTS Remove							

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Ţs
	1		

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTIO Patent Documents at year-USPTIO.GDQ/ or MEPE 901.6.2 Elector office that issued the document, by the holiefler code (WIPO Standard ST.3). 3 For dystagenee platent Countered, by the other code (WIPO Standard ST.3). 3 For dystagenee platent Countered, by the other countered the platent Countered (WIPO Standard ST.16 if possible. 3 Applicant is to place a check mark here if English Brinquise the relation of seatcher.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 GFR 1.99)

Application Number		10816574		
Filing Date		2004-04-01		
First Named Inventor	Shao Xiang Lu			
Art Unit		1616		
Examiner Name	A. Soroush			
Attorney Docket Number		LOREAL 3.0-038		

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98	to make the	appropriate	selection(s):
---------------	----------	----------	-------------	-------------	---------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(4)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Shawn P. Foley/	Date (YYYY-MM-DD)	2007-11-06
Name/Print	Shawn P Foley	Registration Number	33071

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.